- Obalon Therapeutics (OBLN) Q4 results:
- Revenues: $0.9M (-55.0%).
- Net loss: ($4.9M) (+44.3%); loss/share: ($0.64) (+83.5%); CF Ops: ($22.9M) (+22.1%).
- Key Accomplishments in 2019: Promoted Bill Plovanic from CFO to President and CEO.
- Appointed Bob MacDonald as Chief Retail Officer.
- Promoted Nooshin Hussainy from Vice President of Finance to CFO.
- Entered into one-year distribution agreement with distributor for Qatar.
- Opened the first Obalon-managed retail treatment center in San Diego.
- Commercialized Obalon Navigation System and Obalon Touch Inflation Dispenser.
- Shares are down 13% premarket.
- Previously: Obalon Therapeutics EPS misses by $0.09, beats on revenue (Feb. 27)